AI-driven biotechnology company advancing new medicines. Xaira Therapeutics is an integrated biotechnology company pioneering AI-driven drug discovery and development. The company merges foundational machine learning research to understand biology, extensive data generation to train advanced models, and therapeutic product development across different modalities. Headquartered in the San Francisco Bay Area, Xaira launched in 2024 with over USD 1 billion in committed capital from premier investors such as ARCH Venture Partners, Foresite Labs, F-Prime, NEA, Sequoia Capital, Lightspeed, Menlo Ventures, and Two Sigma. It is led by CEO Dr. Marc Tessier-Lavigne, with a leadership team including notable scientific and business co-founders. Xaira integrates expert teams from Illumina’s functional genomics R&D and Interline Therapeutics’ proteomics division, creating a robust platform to accelerate the journey from biological insights to transformative medicines. The company currently employs approximately 110 people.